^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CUSP06

    i
    Other names: CUSP06, AMT-707, CUSP-06
    Company:
    Multitude Therap, OnCusp
    Drug class:
    Topoisomerase I inhibitor, CDH6-targeted antibody-drug conjugate
    Related drugs:
    2ms
    CUSP06-1001: A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=263, Recruiting, OnCusp Therapeutics, Inc. | N=180 --> 263
    Enrollment change • First-in-human
    |
    CUSP06
    3ms
    CUSP06, a Novel CDH6-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Multiple CDH6-Expressing Human Cancer Models. (PubMed, Pharmaceutics)
    CUSP06 demonstrated a favorable safety profile in GLP-compliant toxicology studies in Sprague Dawley rats and cynomolgus monkeys. The preclinical data highlighted the therapeutic potential of CUSP06 in multiple CDH6-positive human cancers.
    Preclinical • Journal
    |
    CDH6 (Cadherin 6)
    |
    CUSP06
    almost2years
    A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=180, Recruiting, OnCusp Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CUSP06
    almost2years
    A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=180, Not yet recruiting, OnCusp Therapeutics, Inc.
    New P1 trial
    |
    CUSP06